within Pharmacolibrary.Drugs.ATC.N;

model N03AC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 8.333333333333332e-07,
    adminDuration  = 600,
    adminMass      = 900 / 1000000,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Trimethadione</td></tr><tr><td>ATC code:</td><td>N03AC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>900</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>50</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Trimethadione is an anticonvulsant medication from the oxazolidinedione class, primarily used in the past for the treatment of absence (petit mal) seizures. Due to its side effect profile and the availability of safer alternatives, its use is now largely historical, and the drug is rarely prescribed in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients (normal renal and hepatic function) after oral administration.</p><h4>References</h4><ol><li><p>Löscher, W, et al., &amp; Schmidt, D (1985). Evaluation of epileptic dogs as an animal model of human epilepsy. <i>Arzneimittel-Forschung</i> 35(1) 82–87. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4039156/\">https://pubmed.ncbi.nlm.nih.gov/4039156</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end N03AC02;
